ProCE Banner Activity

Phase III ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide Alone as Maintenance After ASCT in Patients With NDMM

Slideset Download
Conference Coverage
In this interim analysis, use of post-ASCT carfilzomib/lenalidomide/dexamethasone with an MRD-directed, risk-adapted approach was associated with an improvement in PFS vs standard lenalidomide maintenance.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab